Glaucoma Treatment Market By Indication, By Drug Class, By Sales Channel, and Geography  

Glaucoma Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Congenital Glaucoma, Secondary Glaucoma, and Others), By Drug Class (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Carbonic Anhydrase Inhibitors, and Others), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales), and Region  

Glaucoma Treatment Market size was valued at US$ 7.91 billion in 2022 and is projected to reach US$ 13.53 billion by 2029, growing at a CAGR of 6.98% from 2023 to 2029. Glaucoma is known as the silent thief of sight because most kinds of the disease generate no discomfort or symptoms until significant vision loss occurs. Glaucoma is a collection of eye illnesses that develop when the optic nerve, which transmits information from the eye to the brain, is damaged. The majority of cases are linked to ocular hypertension, a condition in which the pressure inside the eye is higher than normal, although it can also happen when the intraocular pressure is normal. If left untreated, it causes peripheral vision loss, which then progresses to permanent blindness. Glaucoma is the world's second largest cause of blindness. During normal eye exams, a tonometer is used to measure intraocular pressure (IOP). IOP should be less than 21 mmHg in most cases. Glaucoma treatment options include surgery, laser treatment, and medication, depending on the severity of the condition. The majority of eye drops are used to reduce IOP, which is the initial line of defence against glaucoma. Most people are casual about using eye drops correctly, and failing to take prescribed prescription is a primary cause of blindness. Glaucoma Treatment Market owing to rising prevalence of Glaucoma. For instance, WHO estimates that 4.5 million people are blind due to Glaucoma. In India, Glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. Moreover, around 90+ percent of the cases of the glaucoma are undiagnosed in the community. In 2010, around 1.9% of the people in United States age 40 and older. Additionally, technological advancements in the field of ophthalmology and increasing initiatives regarding the awareness of Glaucoma to make aware of the deadly disease. For instance, in March 2020, theme named sneak thief of sight has been hosted at Gandhi Thidal as part of a campaign to raise glaucoma awareness. In India, only 5-10% of the people are aware of the disease. However, stringent approval process coupled with the side effects associated with the products are the major factors hampering the growth of the market.

Glaucoma Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.98%

Largest Market

North America

Fastest Growing Market

Europe

Glaucoma Treatment Market Dynamics

Glaucoma is the second leading cause of blindness, globally and is the top cause of irreversible blindness in the world. For instance, According to WHO estimates, more than 60 million patients are suffering from glaucoma worldwide, as per 2019 statistics. According to the Glaucoma Research Foundation, in the United States, more than 120,000 patients are blind from glaucoma. Thus, owing to the increasing cases of glaucoma the market is anticipated to witness high growth over the forecast period.

Glaucoma Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2022

US$ 7.91 billion

Market Size in 2029

US$ 13.53 billion

Market CAGR

6.98%

By Indication

  • Open Angle Glaucoma
  • Closed Angle Glaucoma
  • Congenital Glaucoma
  • Secondary Glaucoma
  • Others

By Drug Class

  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Carbonic Anhydrase Inhibitors
  • Others

By Sales Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

By Region

North America

  • USA
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Glaucoma Treatment Market size was valued at US$ 7.91 billion in 2022 and is projected to reach US$ 13.53 billion by 2029, growing at a CAGR of 6.98% from 2023 to 2029.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Glaucoma Treatment Market Introduction 
2.1.Global Glaucoma Treatment Market  - Taxonomy
2.2.Global Glaucoma Treatment Market  - Definitions
2.2.1.Indication
2.2.2.Drug Class
2.2.3.Sales Channel
2.2.4.Region
3.Global Glaucoma Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Glaucoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Glaucoma Treatment Market  By Indication, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Open Angle Glaucoma
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Closed Angle Glaucoma
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Congenital Glaucoma
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Secondary Glaucoma
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Glaucoma Treatment Market  By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Alpha Agonist
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Beta Blockers
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Prostaglandin Analogs
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Carbonic Anhydrase Inhibitors
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Glaucoma Treatment Market  By Sales Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Sales
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Glaucoma Treatment Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Open Angle Glaucoma
9.1.2.Closed Angle Glaucoma
9.1.3.Congenital Glaucoma
9.1.4.Secondary Glaucoma
9.1.5.Others
9.2.  Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Alpha Agonist
9.2.2.Beta Blockers
9.2.3.Prostaglandin Analogs
9.2.4.Carbonic Anhydrase Inhibitors
9.2.5.Others
9.3.  Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Sales
9.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Indication Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Open Angle Glaucoma
10.1.2.Closed Angle Glaucoma
10.1.3.Congenital Glaucoma
10.1.4.Secondary Glaucoma
10.1.5.Others
10.2.  Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Alpha Agonist
10.2.2.Beta Blockers
10.2.3.Prostaglandin Analogs
10.2.4.Carbonic Anhydrase Inhibitors
10.2.5.Others
10.3.  Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Sales
10.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
10.4.7.
11.Asia Pacific (APAC) Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Indication Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Open Angle Glaucoma
11.1.2.Closed Angle Glaucoma
11.1.3.Congenital Glaucoma
11.1.4.Secondary Glaucoma
11.1.5.Others
11.2.  Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Alpha Agonist
11.2.2.Beta Blockers
11.2.3.Prostaglandin Analogs
11.2.4.Carbonic Anhydrase Inhibitors
11.2.5.Others
11.3.  Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Sales
11.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Indication Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Open Angle Glaucoma
12.1.2.Closed Angle Glaucoma
12.1.3.Congenital Glaucoma
12.1.4.Secondary Glaucoma
12.1.5.Others
12.2.  Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Alpha Agonist
12.2.2.Beta Blockers
12.2.3.Prostaglandin Analogs
12.2.4.Carbonic Anhydrase Inhibitors
12.2.5.Others
12.3.  Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Sales
12.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Indication Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Open Angle Glaucoma
13.1.2.Closed Angle Glaucoma
13.1.3.Congenital Glaucoma
13.1.4.Secondary Glaucoma
13.1.5.Others
13.2.  Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Alpha Agonist
13.2.2.Beta Blockers
13.2.3.Prostaglandin Analogs
13.2.4.Carbonic Anhydrase Inhibitors
13.2.5.Others
13.3.  Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Sales
13.4.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Novartis AG
14.2.2.Akorn, Incorporated
14.2.3.Inotek Pharmaceuticals
14.2.4.Aerie Pharmaceuticals Inc.
14.2.5.Merck & Co., Inc.
14.2.6.Pfizer Inc
14.2.7.Abbvie Inc. (Allergan Plc)
14.2.8.Santen Pharmaceutical Co., Ltd.
14.2.9.Bausch Health (Bausch & Lomb Incorporated)
14.2.10.Teva Pharmaceuticals
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Novartis AG
  • Akorn, Incorporated
  • Inotek Pharmaceuticals
  • Aerie Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Abbvie Inc. (Allergan Plc)
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health (Bausch & Lomb Incorporated)
  • Teva Pharmaceuticals

 

Related Industry Reports